IDH1 and melanoma: Further, although early studies could not find any IDH mutations in other types of solid tumors (Bleeker et al., 2009; Kang et al., 2009), recurrent mutations have since been identified in chondrosarcoma (56%), cholangiocarcinoma (23%), melanoma (10%), and prostate cancer (2%) (Amary et al., 2011; Borger et al., 2012; Ghiam et al., 2012; Shibata et al., 2011).